2024
Identification of abnormal airway niches in the fibrotic lung using spatial transcriptomics
Justet A, Ravaglia C, Zhao A, Adams N, Agshin B, Kaminski N, Tomasseti S, Poletti V. Identification of abnormal airway niches in the fibrotic lung using spatial transcriptomics. Revue Des Maladies Respiratoires 2024, 41: 215. DOI: 10.1016/j.rmr.2024.01.068.Peer-Reviewed Original ResearchVascular endothelial cellsIPF patientsIPF lungsEpithelial cellsLung tissueEndothelial cellsCOVID patientsAirway epithelial cellsAbnormal cell populationsAlveolar epithelial cellsProgression to fibrosisLong COVIDBasaloid cellsControl patientsImmune cellsGene panelFFPE slidesFibrotic lungsProximal airwaysPatientsDistal lungLungBasal cellsCell populationsLong COVID patients
2023
An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model
Charkoftaki G, Aalizadeh R, Santos-Neto A, Tan W, Davidson E, Nikolopoulou V, Wang Y, Thompson B, Furnary T, Chen Y, Wunder E, Coppi A, Schulz W, Iwasaki A, Pierce R, Cruz C, Desir G, Kaminski N, Farhadian S, Veselkov K, Datta R, Campbell M, Thomaidis N, Ko A, Thompson D, Vasiliou V. An AI-powered patient triage platform for future viral outbreaks using COVID-19 as a disease model. Human Genomics 2023, 17: 80. PMID: 37641126, PMCID: PMC10463861, DOI: 10.1186/s40246-023-00521-4.Peer-Reviewed Original ResearchConceptsCOVID-19 patientsDisease severityViral outbreaksFuture viral outbreaksLength of hospitalizationIntensive care unitWorse disease prognosisLife-threatening illnessEffective medical interventionsCOVID-19Clinical decision treeGlucuronic acid metabolitesNew potential biomarkersHospitalization lengthCare unitComorbidity dataSerotonin levelsDisease progressionHealthy controlsPatient outcomesDisease prognosisPatient transferPatientsHealthcare resourcesPotential biomarkersRational engineering of lung alveolar epithelium
Leiby K, Yuan Y, Ng R, Raredon M, Adams T, Baevova P, Greaney A, Hirschi K, Campbell S, Kaminski N, Herzog E, Niklason L. Rational engineering of lung alveolar epithelium. Npj Regenerative Medicine 2023, 8: 22. PMID: 37117221, PMCID: PMC10147714, DOI: 10.1038/s41536-023-00295-2.Peer-Reviewed Original Research
2022
BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact
De Sadeleer LJ, Verleden SE, Schupp JC, McDonough JE, Goos T, Yserbyt J, Bargagli E, Rottoli P, Kaminski N, Prasse A, Wuyts WA. BAL Transcriptomes Characterize Idiopathic Pulmonary Fibrosis Endotypes With Prognostic Impact. CHEST Journal 2022, 161: 1576-1588. PMID: 35063449, PMCID: PMC9424328, DOI: 10.1016/j.chest.2021.12.668.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF samplesIndependent validation cohortAvailable gene expression datasetsClinical characteristicsPrognostic impactWorse survivalPathophysiologic mechanismsPulmonary fibrosisClinical evolutionClinical variablesValidation cohortEnrichment analysisBAL samplesSurvival-associated genesBlood samplesEndotypesStudy designControl participantsMitochondrial dysfunctionPatientsFibrosisSurvivalTranscription factorsNumeric trendsMetagenomic sequencing of the bronchoalveolar lavage extracellular virome and cellular transcriptome of sarcoidosis patients does not detect rubella virus
Keeler E, Vukmirovic M, Yan X, Gulino K, Ghedin E, Kaminski N, Sullivan K, Bushman F, Collman R, Rosenbach M. Metagenomic sequencing of the bronchoalveolar lavage extracellular virome and cellular transcriptome of sarcoidosis patients does not detect rubella virus. Sarcoidosis, Vasculitis, And Diffuse Lung Diseases 2022, 39: e2022040. PMID: 36533601, PMCID: PMC9798337, DOI: 10.36141/svdld.v39i4.13407.Peer-Reviewed Original ResearchSarcoidosis patientsRubella virusBronchoalveolar lavageMultisystem granulomatous inflammatory diseaseImmune-competent patientsRubella virus infectionGranulomatous inflammatory diseaseCutaneous sarcoidosisAntigenic triggerBAL cellsUnclear etiologyRubella virus genomeInflammatory diseasesCutaneous granulomasGranulomatous lesionsVirus infectionVirus gene expressionLung samplesAcellular fluidCompetent patientsPatientsSarcoidosisOverlapping featuresMetagenomic sequencingVirus
2021
Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19
Hoehn KB, Ramanathan P, Unterman A, Sumida TS, Asashima H, Hafler DA, Kaminski N, Dela Cruz CS, Sealfon SC, Bukreyev A, Kleinstein SH. Cutting Edge: Distinct B Cell Repertoires Characterize Patients with Mild and Severe COVID-19. The Journal Of Immunology 2021, 206: 2785-2790. PMID: 34049971, PMCID: PMC8627528, DOI: 10.4049/jimmunol.2100135.Peer-Reviewed Original ResearchConceptsSevere COVID-19Mild COVID-19B cell responsesMemory B cellsB cell repertoireB cellsCell repertoireCOVID-19Cell responsesExtrafollicular B cell responsesLong-term immunitySymptomatic COVID-19Onset of symptomsB cell populationsGerminal center reactionProtective immunityPlasma cellsSingle-cell RNA sequencingCenter reactionPatientsCell populationsImmunityRNA sequencingCellsPostvaccinationImmune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children
Ramaswamy A, Brodsky NN, Sumida TS, Comi M, Asashima H, Hoehn KB, Li N, Liu Y, Shah A, Ravindra NG, Bishai J, Khan A, Lau W, Sellers B, Bansal N, Guerrerio P, Unterman A, Habet V, Rice AJ, Catanzaro J, Chandnani H, Lopez M, Kaminski N, Dela Cruz CS, Tsang JS, Wang Z, Yan X, Kleinstein SH, van Dijk D, Pierce RW, Hafler DA, Lucas CL. Immune dysregulation and autoreactivity correlate with disease severity in SARS-CoV-2-associated multisystem inflammatory syndrome in children. Immunity 2021, 54: 1083-1095.e7. PMID: 33891889, PMCID: PMC8043654, DOI: 10.1016/j.immuni.2021.04.003.Peer-Reviewed Original ResearchConceptsMIS-C patientsDisease severityInflammatory syndromeTCR repertoireSARS-CoV-2-associated multisystem inflammatory syndromeAsymptomatic SARS-CoV-2 infectionSARS-CoV-2 infectionAdult COVID-19Post-infectious complicationsMultisystem inflammatory syndromeCytotoxicity genesHealthy pediatricImmune dysregulationMemory TActive infectionMyeloid dysfunctionPatientsSingle-cell RNA sequencingFlow cytometrySerum proteomicsRepertoire analysisElevated expressionSeverityAlarminsCOVID-19
2018
S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension
Tzouvelekis A, Herazo‐Maya J, Ryu C, Chu J, Zhang Y, Gibson KF, Adonteng‐Boateng P, Li Q, Pan H, Cherry B, Ahmad F, Ford HJ, Herzog EL, Kaminski N, Fares WH. S100A12 as a marker of worse cardiac output and mortality in pulmonary hypertension. Respirology 2018, 23: 771-779. PMID: 29611244, PMCID: PMC6047907, DOI: 10.1111/resp.13302.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsPH patientsPH cohortCardiac outputWorld Health Organization group 1Idiopathic pulmonary fibrosis patientsPulmonary hypertension patientsPulmonary fibrosis patientsBlood mononuclear cellsProtein serum concentrationsHigher S100A12Pulmonary hypertensionS100A12 levelsOverall mortalityHypertension patientsPrognostic valueValidation cohortMononuclear cellsPeripheral bloodSerum concentrationsInflammatory diseasesGroup 1PatientsFibrosis patientsS100A12
2017
Chapter 7 MicroRNAs in Idiopathic Pulmonary Fibrosis Partners in Health and Disease
Pandit K, Kaminski N. Chapter 7 MicroRNAs in Idiopathic Pulmonary Fibrosis Partners in Health and Disease. 2017, 179-202. DOI: 10.1016/b978-0-12-800553-8.00007-x.Peer-Reviewed Original ResearchIdiopathic pulmonary fibrosisEtiology of IPFInterstitial lung diseaseExtent of fibrosisIPF patientsPulmonary fibrosisIrreversible scarringLung diseaseTreatment optionsAggressive formPotent cytokineGrowth factorDiseaseDreadful diseaseFibrosisLungTGFCurrent knowledgeMicroRNAsTarget genesGas exchangePatientsCytokinesScarringEtiology
2016
Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies
Tan J, Tedrow JR, Dutta JA, Juan-Guardela B, Nouraie M, Chu Y, Trejo Bittar H, Ramani K, Biswas PS, Veraldi KL, Kaminski N, Zhang Y, Kass DJ. Expression of RXFP1 Is Decreased in Idiopathic Pulmonary Fibrosis. Implications for Relaxin-based Therapies. American Journal Of Respiratory And Critical Care Medicine 2016, 194: 1392-1402. PMID: 27310652, PMCID: PMC5148141, DOI: 10.1164/rccm.201509-1865oc.Peer-Reviewed Original ResearchConceptsRelaxin/insulin-like family peptide receptor 1Idiopathic pulmonary fibrosisIPF lung fibroblastsRXFP1 expressionLung fibroblastsPulmonary fibrosisFamily peptide receptor 1RXFP1 gene expressionLung Tissue Research ConsortiumPulmonary functionIPF lungsBleomycin injuryPotential therapyCollagen depositionFibrotic diseasesPatientsDemographic dataPotential efficacyReceptor 1Donor controlsTherapyRelaxin-like peptideGrowth factorGene expressionFibrosis
2015
Palliative Care and Location of Death in Decedents With Idiopathic Pulmonary Fibrosis
Lindell KO, Liang Z, Hoffman LA, Rosenzweig MQ, Saul MI, Pilewski JM, Gibson KF, Kaminski N. Palliative Care and Location of Death in Decedents With Idiopathic Pulmonary Fibrosis. CHEST Journal 2015, 147: 423-429. PMID: 25187973, PMCID: PMC4314817, DOI: 10.1378/chest.14-1127.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisLocation of deathPalliative care referralPalliative careCare referralPulmonary fibrosisAdequacy of endCommunity hospital wardsLung transplant recipientsTiming of referralMajority of patientsObituary listingsTransplant recipientsMedian survivalSymptom burdenSpecialty centersFirst visitHospital settingCenter visitsHospital wardsClinical practiceReferralPatientsDecedentsCareUpdate in Diffuse Parenchymal Lung Disease 2013
Rosas IO, Kaminski N. Update in Diffuse Parenchymal Lung Disease 2013. American Journal Of Respiratory And Critical Care Medicine 2015, 191: 270-274. PMID: 25635490, PMCID: PMC4351573, DOI: 10.1164/rccm.201405-0856up.Peer-Reviewed Original ResearchMeSH KeywordsAnti-Inflammatory Agents, Non-SteroidalClinical Trials, Phase III as TopicDisease ProgressionDrug ApprovalEnzyme InhibitorsGenomicsHumansIdiopathic Pulmonary FibrosisIndolesLung Diseases, InterstitialPolymorphism, GeneticPyridonesTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationConceptsMajority of patientsDistinct clinical presentationsSignificant clinical implicationsClinical presentationPulmonary fibrosis researchDisease progressionClinical implicationsGenetic biomarkersPatientsFibrosis researchGenetic variantsBiological mechanismsIPFNew biological mechanismsNintedanibPirfenidonePeriodHistoric approvalOral immunotherapy with type V collagen in idiopathic pulmonary fibrosis
Wilkes DS, Chew T, Flaherty KR, Frye S, Gibson KF, Kaminski N, Klemsz MJ, Lange W, Noth I, Rothhaar K. Oral immunotherapy with type V collagen in idiopathic pulmonary fibrosis. European Respiratory Journal 2015, 45: 1393-1402. PMID: 25614165, DOI: 10.1183/09031936.00105314.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisIPF patientsPulmonary fibrosisHigh-dose cohortLow-dose cohortSerious adverse eventsPhase 1 studyProgressive lung diseaseType V collagenPrecision medicine approachMatrix metalloproteinase-7Acute exacerbationIPF trialsOral immunotherapyAdverse eventsPlacebo armLung functionPoor prognosisVital capacityLung diseaseImmune responsePatientsMetalloproteinase-7Potential efficacyMedicine approach
2014
Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report
Blackwell TS, Tager AM, Borok Z, Moore BB, Schwartz DA, Anstrom KJ, Bar-Joseph Z, Bitterman P, Blackburn MR, Bradford W, Brown KK, Chapman HA, Collard HR, Cosgrove GP, Deterding R, Doyle R, Flaherty KR, Garcia CK, Hagood JS, Henke CA, Herzog E, Hogaboam CM, Horowitz JC, King TE, Loyd JE, Lawson WE, Marsh CB, Noble PW, Noth I, Sheppard D, Olsson J, Ortiz LA, O’Riordan T, Oury TD, Raghu G, Roman J, Sime PJ, Sisson TH, Tschumperlin D, Violette SM, Weaver TE, Wells RG, White ES, Kaminski N, Martinez FJ, Wynn TA, Thannickal VJ, Eu JP. Future Directions in Idiopathic Pulmonary Fibrosis Research. An NHLBI Workshop Report. American Journal Of Respiratory And Critical Care Medicine 2014, 189: 214-222. PMID: 24160862, PMCID: PMC3983890, DOI: 10.1164/rccm.201306-1141ws.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIdiopathic pulmonary fibrosisAlveolar epithelial injuryEffective medical therapyRole of inflammationTime of diagnosisPatient advocacy groupsMedian survivalMedical therapyEpithelial injuryPulmonary fibrosisPulmonary fibrosis researchIPF therapyIPF researchPreclinical modelingDrug AdministrationPatient communityU.S. FoodNHLBITranslation of discoveriesClinical researchersPatientsFibrosis researchTherapyDiseaseAberrant repair
2013
Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression.
Chien JW, Richards TJ, Gibson KF, Zhang Y, Lindell KO, Shao L, Lyman SK, Adamkewicz JI, Smith V, Kaminski N, O'Riordan T. Serum lysyl oxidase-like 2 levels and idiopathic pulmonary fibrosis disease progression. European Respiratory Journal 2013, 43: 1430-8. PMID: 24177001, DOI: 10.1183/09031936.00141013.Peer-Reviewed Original ResearchConceptsIPF disease progressionDisease progressionIdiopathic pulmonary fibrosis patientsCarbon monoxide diffusion capacityPulmonary fibrosis patientsDisease progression eventsGAP subjectsIPF studiesPathological stromaVital capacityLOXL2 levelsProgression eventsDiffusion capacityFibrosis patientsSpirometric dataDisease severityPhysiological surrogatesProgressionPatientsRiskMultiple limitationsSubjectsLevelsProteomic analysisCohort
2012
Biomarkers in idiopathic pulmonary fibrosis
Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Current Opinion In Pulmonary Medicine 2012, 18: 441-446. PMID: 22847105, PMCID: PMC4165635, DOI: 10.1097/mcp.0b013e328356d03c.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPeripheral blood biomarkersPulmonary fibrosisBlood biomarkersDisease presenceMultiple clinical contextsPeripheral bloodPredictive biomarkersGene polymorphismsLarger studyDrug studiesOutcome trajectoriesPrediction ruleClinical contextBiomarkersMolecular biomarkersMultiple studiesPatientsFibrosisSufficient evidenceOutcomesProtein markersConvincing evidenceRecent studiesMarkersPersonalized medicine: applying omics to lung fibrosis
Herazo-Maya JD, Kaminski N. Personalized medicine: applying omics to lung fibrosis. Biomarkers In Medicine 2012, 6: 529-540. PMID: 22917154, PMCID: PMC3517740, DOI: 10.2217/bmm.12.38.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisFibrotic lung diseaseLung transplantPulmonary fibrosisLung fibrosisLung diseaseUnknown etiologyChronic diseasesSporadic formsHigh mortalityPatient careTreatment of diseasesDrug studiesCost-effective strategyDiseaseFibrosisDiagnosisPersonalized medicinePatientsTransplantEtiologyTherapyMortalityCarePreventionRetinoic Acid–related Orphan Receptor-α Is Induced in the Setting of DNA Damage and Promotes Pulmonary Emphysema
Shi Y, Cao J, Gao J, Zheng L, Goodwin A, An CH, Patel A, Lee JS, Duncan SR, Kaminski N, Pandit KV, Rosas IO, Choi AM, Morse D. Retinoic Acid–related Orphan Receptor-α Is Induced in the Setting of DNA Damage and Promotes Pulmonary Emphysema. American Journal Of Respiratory And Critical Care Medicine 2012, 186: 412-419. PMID: 22744720, PMCID: PMC5450975, DOI: 10.1164/rccm.201111-2023oc.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBiomarkersCells, CulturedDisease Models, AnimalDNA DamageDNA RepairGene Expression ProfilingHumansLungMiceMice, Inbred C57BLMice, Neurologic MutantsNuclear Receptor Subfamily 1, Group F, Member 1Oligonucleotide Array Sequence AnalysisPulmonary Disease, Chronic ObstructivePulmonary EmphysemaTobacco Smoke PollutionConceptsRetinoic acid-related orphan receptorAcid-related orphan receptorCigarette smoke extractLungs of patientsPathogenesis of emphysemaRORA expressionCigarette smokeAirspace enlargementSmoke extractCigarette smoke exposureSmoke-induced emphysemaOrphan receptorDNA damageActive smokingLung transplantationSmoke exposureLung cancerPulmonary emphysemaLung tissueEmphysemaPatientsGene expression profilingApoptotic cell deathMiceEnhanced susceptibilityTranslational Value Of The Bleomycin Rat Model For The Treatment Of Patients With Idiopathic Pulmonary Fibrosis (IPF)
Bauer Y, Gibson K, Guardella B, Hess P, Klenk A, Lindell K, Renault B, Rey M, Tedrow J, Weber E, Kaminski N, Nayler O. Translational Value Of The Bleomycin Rat Model For The Treatment Of Patients With Idiopathic Pulmonary Fibrosis (IPF). 2012, a6241-a6241. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6241.Peer-Reviewed Original ResearchDoes The Oxygen Prescription Match The Study Results?: A Prospective Study Of Patients In A Speciality Interstitial Lung Disease Center
Pagnotta E, MacPherson M, Gibson K, Kaminski N, Lindell K. Does The Oxygen Prescription Match The Study Results?: A Prospective Study Of Patients In A Speciality Interstitial Lung Disease Center. 2012, a1490-a1490. DOI: 10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a1490.Peer-Reviewed Original Research